ACR: Long-Term Biologic Use in RA Cuts MI, Cancer Risk (CME/CE)
CHICAGO (MedPage Today) — Long-term treatment with the biologic agent etanercept (Enbrel) is not only effective against rheumatoid arthritis, but reduces the patient’s risk of heart attack and malignancy, and may also reduce the risk of death, when compared with therapy using disease-modifying anti-rheumatic drugs, researchers suggested here.
